RFS
ACHN

Rockefeller Financial Services’s Achillion Pharmaceuticals ACHN Stock Holding History

Rockefeller Financial Services’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-28,271
Closed -$250K – 528
2015
Q2 		$250K Buy
28,271
+15,494
+121% +$147K 0.01% 296
2015
Q1 		$126K Buy
+12,777
New +$160K ﹤0.01% 359

Other funds holding ACHN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Rockefeller Financial Services's ACHN Position: Q3 2015 in Review

Rockefeller Financial Services sold out of Achillion Pharmaceuticals (ACHN) in Q3 2015, closing a stake of 28,271 shares — an estimated $250K sold.

Rockefeller Financial Services first reported a position in ACHN in Q1 2015 and held it in 2 quarters. The position peaked at $250K in Q2 2015. 141 funds tracked by Wall St. Rank hold ACHN as of Q3 2015.

  • Rockefeller Financial Services reported no remaining Achillion Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Rockefeller Financial Services sold 28,271 Achillion Pharmaceuticals shares in Q3 2015, an estimated $250K.
  • Rockefeller Financial Services first reported a position in Achillion Pharmaceuticals in Q1 2015 and held it in 2 quarters.
  • Rockefeller Financial Services's Achillion Pharmaceuticals position peaked at $250K in Q2 2015.
  • 141 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q3 2015.

Based on Rockefeller Financial Services's 13F filing for Q3 2015, filed 23 Oct 2015.